JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB177619

Recombinant Human Apolipoprotein CI/Apo-CI (His tag N-Terminus)

Be the first to review this product! Submit a review

|

(1 Publication)

Recombinant Human Apolipoprotein CI/Apo-CI (His tag N-Terminus) is a Human Full Length protein, in the 27 to 83 aa range, expressed in Escherichia coli, with >90%, suitable for SDS-PAGE, Mass Spec.

View Alternative Names

Apolipoprotein C-I, Apo-CI, ApoC-I, Apolipoprotein C1, APOC1

1 Images
SDS-PAGE - Recombinant Human Apolipoprotein CI/Apo-CI (His tag N-Terminus) (AB177619)
  • SDS-PAGE

Supplier Data

SDS-PAGE - Recombinant Human Apolipoprotein CI/Apo-CI (His tag N-Terminus) (AB177619)

3ug by SDS-PAGE under reducing condition and visualized by coomassie blue stain.

Key facts

Purity

>90% SDS-PAGE

Expression system

Escherichia coli

Tags

His tag N-Terminus

Applications

SDS-PAGE, Mass Spec

applications

Biologically active

No

Accession

P02654

Animal free

No

Carrier free

No

Species

Human

Storage buffer

pH: 8 Constituents: 10% Glycerol (glycerin, glycerine), 0.88% Sodium chloride, 0.32% Tris HCl

storage-buffer

style
left-column

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Reactivity", "Dilution Info", "Notes"] }, "values": { "SDS-PAGE": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" }, "Mass Spec": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" } } }
style
left-column

Product details

This product was previously labelled as Apolipoprotein CI
style
left-column

Sequence info

[{"sequence":"MGSSHHHHHHSSGLVPRGSHMGSTPDVSSALDKLKEFGNTLEDKARELISRIKQSELSAKMREWFSETFQKVKEKLKIDS","proteinLength":"Full Length","predictedMolecularWeight":"9 kDa","actualMolecularWeight":null,"aminoAcidEnd":83,"aminoAcidStart":27,"nature":"Recombinant","expressionSystem":"Escherichia coli","accessionNumber":"P02654","tags":[{"tag":"His","terminus":"N-Terminus"}]}]
style
left-column

Properties and storage information

Shipped at conditions
Blue Ice
Appropriate short-term storage duration
1-2 weeks
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
-20°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle
False
style
left-column

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

Apolipoprotein CI (Apo-CI) plays a mechanical role in lipid metabolism where it acts as an inhibitor of lipoprotein lipase and hepatic lipase hindering lipolytic activity. It is also known as 'apo 250' and 'apo atv20' with a molecular mass of approximately 6.6 kDa. Apo-CI is primarily expressed in the liver and secreted into the plasma where it associates with high-density lipoproteins (HDL) and very low-density lipoproteins (VLDL).
Biological function summary

Apo-CI influences plasma triglyceride levels and cholesterol homeostasis. It plays a role in lipid transport and metabolism by modulating the binding of other apolipoproteins such as apo A-IV and interfering with the binding of lipoproteins to their receptors. Apo-CI is part of a complex of apolipoproteins that regulate lipid metabolism working in tandem to balance lipid and cholesterol levels in the body.

Pathways

Apo-CI is actively involved in the lipoprotein metabolism pathway and cholesterol efflux pathway. These pathways are important in maintaining lipid balance and cardiovascular health. Apo-CI is related to other apolipoproteins within these pathways such as apo E and apo A-I. Its function in modulating lipoprotein receptor interactions aligns with the broader mechanisms of these pathways in lipid and cholesterol regulation.

Elevated levels of Apo-CI are associated with hyperlipidemia and cardiovascular disease. These conditions may result from its inhibitory effects on lipase activity leading to increased triglyceride levels. Apo-CI's interaction with other apolipoproteins such as apo B and apo E is linked to its role in the pathogenesis of these disorders. Understanding Apo-CI's involvement in these diseases can guide therapeutic strategies aimed at regulating its expression and function.
style
left-column

Specifications

Form

Liquid

Additional notes

ab177619 is purified by using conventional chromatography techniques.

style
left-column

General info

Function

Inhibitor of lipoprotein binding to the low density lipoprotein (LDL) receptor, LDL receptor-related protein, and very low density lipoprotein (VLDL) receptor. Associates with high density lipoproteins (HDL) and the triacylglycerol-rich lipoproteins in the plasma and makes up about 10% of the protein of the VLDL and 2% of that of HDL. Appears to interfere directly with fatty acid uptake and is also the major plasma inhibitor of cholesteryl ester transfer protein (CETP). Binds free fatty acids and reduces their intracellular esterification. Modulates the interaction of APOE with beta-migrating VLDL and inhibits binding of beta-VLDL to the LDL receptor-related protein.

Sequence similarities

Belongs to the apolipoprotein C1 family.

style
left-column

Product protocols

style
left-column

Target data

Inhibitor of lipoprotein binding to the low density lipoprotein (LDL) receptor, LDL receptor-related protein, and very low density lipoprotein (VLDL) receptor. Associates with high density lipoproteins (HDL) and the triacylglycerol-rich lipoproteins in the plasma and makes up about 10% of the protein of the VLDL and 2% of that of HDL. Appears to interfere directly with fatty acid uptake and is also the major plasma inhibitor of cholesteryl ester transfer protein (CETP). Binds free fatty acids and reduces their intracellular esterification. Modulates the interaction of APOE with beta-migrating VLDL and inhibits binding of beta-VLDL to the LDL receptor-related protein.
See full target information APOC1
style
left-column

Publications (1)

Recent publications for all applications. Explore the full list and refine your search

iScience 24:103538 PubMed34917906

2021

CD95/Fas suppresses NF-κB activation through recruitment of KPC2 in a CD95L/FasL-independent mechanism.

Applications

Unspecified application

Species

Unspecified reactive species

Jean-Philippe Guégan,Justine Pollet,Christophe Ginestier,Emmanuelle Charafe-Jauffret,Marcus E Peter,Patrick Legembre
View all publications
style
left-column
style
left-column
style
right-column

Complementary Products

Proteins & Peptides

AB280330

Recombinant human Apolipoprotein E3

Mass Spectrometry - Recombinant human Apolipoprotein E3 (AB280330)

  • 0
  • 0
Proteins & Peptides

AB322097

Recombinant Mouse APOA1 Protein Standard (His tag)

Sandwich ELISA - Recombinant Mouse APOA1 Protein Standard (His tag) (AB322097)

  • 0
  • 0
Primary Antibodies

AB139401

Anti-Apolipoprotein B antibody [EPR2914]

RabMAb|Recombinant

Western blot - Anti-Apolipoprotein B antibody [EPR2914] (AB139401)

  • 0
  • 0
Proteins & Peptides

AB174391

Recombinant Human Apolipoprotein A V/APOA5 - BSA and Azide free (denatured) (His tag N-Terminus)

SDS-PAGE - Recombinant Human Apolipoprotein A V/APOA5 - BSA and Azide free (denatured) (His tag N-Terminus) (AB174391)

  • 0
  • 0

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com